Cargando…
Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept
Chloroquine and hydroxychloroquine have been proposed recently as therapy for SARS-CoV-2-infected patients, but during 3 months of extensive use concerns were raised related to their clinical effectiveness and arrhythmogenic risk. Therefore, we estimated for these compounds several proarrhythmogenic...
Autores principales: | Thomet, Urs, Amuzescu, Bogdan, Knott, Thomas, Mann, Stefan A., Mubagwa, Kanigula, Radu, Beatrice Mihaela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590616/ https://www.ncbi.nlm.nih.gov/pubmed/34785211 http://dx.doi.org/10.1016/j.ejphar.2021.174632 |
Ejemplares similares
-
CiPA-compliant assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine
por: Amuzescu, Bogdan, et al.
Publicado: (2021) -
Introduction to in silico model for proarrhythmic risk assessment under the CiPA initiative
por: Park, Jin-Sol, et al.
Publicado: (2019) -
Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
por: Li, Zhihua, et al.
Publicado: (2018) -
Five years of the CiPA project (2013–2018): what did we learn?
por: Yim, Dong-Seok
Publicado: (2018) -
In silico assessment on TdP risks of drug combinations under CiPA paradigm
por: Qauli, Ali Ikhsanul, et al.
Publicado: (2023)